Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Is Cannabis Dronabinol for Sleep Apnoea Part of Any National Sleep Guidelines? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

The inclusion of dronabinol guidelines in national recommendations for obstructive sleep apnoea (OSA) remains limited. While dronabinol has shown some potential in reducing apnoea-hypopnea index, its role in routine treatment is still under evaluation. 

Am I eligible for medical cannabis for pain relief?

National Guidance Overview 

Current dronabinol guidelines indicate that cannabinoid therapy for OSA is largely experimental. Most national sleep organisations do not yet endorse dronabinol as a standard therapy. 

Evidence-Based Recommendations 

The national sleep guidelines for dronabinol highlight that research is restricted to small-scale trials, with short follow-up periods. Clinicians are advised to prioritise established therapies, such as CPAP, before considering dronabinol. 

Policy Considerations 

The policy for dronabinol for OSA emphasises cautious use, typically within clinical trials or under specialised supervision, due to limited long-term safety and efficacy data. 

Safety and Monitoring 

Guidelines underscore monitoring for sedation, cardiovascular effects, and potential tolerance, reinforcing careful patient selection when following dronabinol guidelines. 

Overall, dronabinol guidelines show that while dronabinol is a promising adjunct for OSA, national sleep authorities currently classify it as investigational. The national sleep guidelines for dronabinol and policy for dronabinol for OSA both call for further research before it can be recommended for widespread clinical use. 

If you’re exploring cannabis treatment options for obstructive sleep apnoea, visit providers like LeafEase for personalised consultations and guidance tailored to your needs. 

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Obstructive Sleep Apnoea. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories